Southwest Autism Research & Resource Center

Phoenix, Arizona 85006

2 studies enrolling now · 21 studies all time

What they study most

Autism, Autism Spectrum Disorder, Autism Spectrum Disorders, Down Syndrome, Fragile X Syndrome, Irritability Associated With Autism Spectrum Disorder, Weight, Body

Studies at this site

• Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM) — Recruiting now
• Telehealth Mindfulness-based Intervention for Adolescents With Autism Spectrum Disorder and Their Caregivers — Recruiting now
• Long-term Antipsychotic Pediatric Safety Trial — Completed
• Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder — Completed
• A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension — Stopped early
• A Study to Investigate the Efficacy and Safety of Balovaptan (RO5285119) in Participants With Autism Spectrum Disorder (ASD) — Stopped early
• A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Balovaptan in Children With Autism Spectrum Disorder — Stopped early
• A Study of RO5186582 in Down Syndrome Among Children 6 to 11 Years of Age — Stopped early
• A Study of RG7314 to Investigate Efficacy and Safety in Individuals With Autism Spectrum Disorders (ASD) — Completed
• A 6-week, Study of MG01CI Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile X Syndrome — Completed
• Lurasidone Pediatric Autism Study — Completed
• Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo in Autism Spectrum Disorder — Stopped early
• Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders — Stopped early
• Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome — Completed
• Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders — Completed
• Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome — Completed
• Biomarker Testing and DNA Collection in Subjects Participating in Protocol 22001 — Completed
• Biomarker and DNA Collection in Subjects Participating in Protocol 22003 — Completed
• Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders — Completed
• Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome — Completed
• An Open Label Extension Study of STX209 in Subjects With Autism Spectrum Disorders — Stopped early